Insulet (NASDAQ:PODD – Get Free Report) had its price objective cut by equities researchers at TD Cowen from $379.00 to $294.00 in a report issued on Monday,MarketScreener reports. The brokerage currently has a “hold” rating on the medical instruments supplier’s stock. TD Cowen’s price objective indicates a potential upside of 102.84% from the company’s current price.
Other equities research analysts have also issued reports about the stock. Barclays decreased their target price on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research note on Thursday, May 7th. Canaccord Genuity Group lowered their target price on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Leerink Partners cut their price target on Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. Stifel Nicolaus lowered their price objective on shares of Insulet from $350.00 to $250.00 in a research note on Thursday, May 7th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $205.00 target price on shares of Insulet in a report on Wednesday. Twenty-one investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average price target of $252.04.
Check Out Our Latest Stock Report on Insulet
Insulet Stock Performance
Insulet (NASDAQ:PODD – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same quarter last year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts anticipate that Insulet will post 6.44 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Avidity Partners Management LP bought a new stake in shares of Insulet in the 1st quarter worth about $2,098,000. Glenmede Trust Co. NA increased its position in shares of Insulet by 6.5% during the 1st quarter. Glenmede Trust Co. NA now owns 2,717 shares of the medical instruments supplier’s stock valued at $570,000 after purchasing an additional 166 shares during the last quarter. Essential Partners LLC lifted its position in Insulet by 9,980.0% in the first quarter. Essential Partners LLC now owns 504 shares of the medical instruments supplier’s stock worth $106,000 after buying an additional 499 shares during the last quarter. Western Wealth Management LLC bought a new stake in Insulet in the first quarter worth $80,000. Finally, Edgestream Partners L.P. boosted its stake in Insulet by 131.1% during the first quarter. Edgestream Partners L.P. now owns 21,645 shares of the medical instruments supplier’s stock worth $4,542,000 after buying an additional 12,277 shares during the period.
About Insulet
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Read More
- Five stocks we like better than Insulet
- SanDisk’s Stock and Short Interest Both at Record Highs —Do the Bears Know Something?
- Alphabet Bets on Hardware With Googlebook and AI Glasses
- Burlington Beat Earnings Estimates, But Not Investor Expectations
- Palantir Stock Faces Technical Pressure Despite Strong AI Growth
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
